We are live on ! Find out more
VRPX

Virpax Pharmaceuticals, Inc. Common Stock
VRPX

Delisted

VRPX was delisted on the 3rd of April, 2025.

Back to rankings

12 hedge funds and large institutions have $828K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $874K → $828K (-$46.1K)

14% less funds holding

Funds holding: 14 → 12 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$9.93K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$250K
2
BAM
Belpointe Asset Management
Nevada
-$14.9K
3
WAM
Warberg Asset Management
Illinois
-$13.4K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$13K
5
Renaissance Technologies
Renaissance Technologies
New York
-$4.97K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$432K -$250K -1,206 -43%
PNC Financial Services Group
2
PNC Financial Services Group
Pennsylvania
$109K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$97K -$4.97K -24 -6%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$72K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$70.4K – – –
Northern Trust
6
Northern Trust
Illinois
$16.4K – – –
TSS
7
Two Sigma Securities
New York
$12.9K +$9.93K +48 New
QPW
8
Quantum Private Wealth
Florida
$10.8K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$5.87K – – –
Osaic Holdings
10
Osaic Holdings
Arizona
$648 – – –
BlackRock
11
BlackRock
New York
$501 – – –
Morgan Stanley
12
Morgan Stanley
New York
$162 – – –
Wells Fargo
13
Wells Fargo
California
$67 – – –
BAM
14
Belpointe Asset Management
Nevada
– -$14.9K -76 Closed
WAM
15
Warberg Asset Management
Illinois
– -$13.4K -68 Closed
Cambridge Investment Research Advisors
16
Cambridge Investment Research Advisors
Iowa
– -$13K -64 Closed
ASN
17
Advisory Services Network
Georgia
– -$97 – –

VRPX Hedge Fund Activity: Q2 2023 in Review

12 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q2 2023, worth a combined $828K — down 5.3% from $874K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of VRPX and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $9.93K. The largest seller was Sabby Management, cutting an estimated $250K.

  • 12 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q2 2023, down from 14 in Q1 2023.
  • Funds reported $828K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q2 2023, down 5.3% quarter-over-quarter.
  • 1 fund opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -2 holders.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Two Sigma Securities, an estimated $9.93K added.
  • The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Sabby Management, an estimated $250K sold.

Based on aggregated 13F filings for Q2 2023.